- Conditions
- Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
- Interventions
- Hemoleven
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- 6 Months and older
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 440
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- Interventions
- Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 390
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
- Conditions
- Premature Birth, Obstetric Labor, Premature
- Interventions
- Micronized progesterone suppository
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- End Stage Renal Disease on Hemodialysis (Diagnosis)
- Interventions
- HEPLISAV-B®
- Drug
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 11,194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 35 more
- Conditions
- Preeclampsia
- Interventions
- Aspirin, placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Female only
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Renal Failure
- Interventions
- LCP-Tacro tablets, Prograf
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- End Stage Renal Disease, ESRD
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 871 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Endometritis
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
- Interventions
- Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment
- Other · Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Gestational Diabetes Mellitus in Pregnancy
- Interventions
- Subjects with Gestational Diabetes, Controls without Gestational Diabetes
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
- Interventions
- Calfactant, Budesonide
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 7 Days to 14 Days
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
- Interventions
- Samples
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Preterm Birth, Activity Restriction, Bed Rest, Low-Value Care
- Interventions
- Multicomponent deimplementation strategy
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Hypertension, Pregnancy-Induced, Hypertension
- Interventions
- Furosemide, Placebo
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Diseases
- Interventions
- MEDI-507
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1998
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Bloomington, Indiana • San Antonio, Texas + 1 more
- Conditions
- Pregnancy Related, Antepartum DVT
- Interventions
- Standard Dose of Unfractionated Heparin, Gestational Age-Based Dose of Unfractionated Heparin
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Systemic Lupus Erythematosus, Contraception
- Interventions
- HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention, Routine Care
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Endometriosis, Ovarian Hyperstimulation
- Interventions
- Placebo oral tablet, Letrozole
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Preterm Birth Complication, Preterm Birth, Preterm Birth Recurrence, Preeclampsia, Preeclampsia (PE), Hypertensive Disorders of Pregnancy, Support Program, Stress, Resilience, Psychological, Empowerment, Patient, Emotional Stress, Pregnancy, Pregnancy Complications, Pregnancy Induced Hypertension, Neonates and Preterm Infants, Cervical Insufficiency, Social Determinants of Health (SDOH), Cervical Shortening, Disparities in Pregnancy Complications, Disparities, Prenatal Care, Care Coordination
- Interventions
- Care coordination, Electronic massage, support gift #1, Support gift #2, Support gift #3, Support gift #4, Additional PTBCARE+ support, Stress reduction toolkit - Visit 1 (V1), PTBCARE+ mobile application (app) and website, Sleep, meditation, and Wellness app, Emergency low blood sugar kit, Low dose aspirin (LDA), Visit #2 Stress Reduction Toolkit
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Prevention of Pregnancy
- Interventions
- Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 938 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more
- Conditions
- Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
- Interventions
- Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21
- Procedure · Drug · Biological
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cancer
- Interventions
- fluconazole, itraconazole
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1992
- U.S. locations
- 187
- States / cities
- Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more